Dosimetric Outcomes of Definitive Radiation Therapy to Anal Squamous Cell Carcinoma in a Single Institution Using Volumetric Modulated Arc Therapy Evaluated Against Australian and International Treatment Planning Guidelines
- 1Department of Radiation Oncology, Mid North Coast Cancer Institute, Coffs Harbour Health Campus, Coffs Harbour, New South Wales, Australia.
- 2RCS Faculty of Medicine, University of New South Wales, Coffs Harbour, New South Wales, Australia.
Abstract
Introduction
Volumetric Modulated Arc Therapy (VMAT) is the technique of choice for anal Squamous Cell Carcinoma (SCC), offering highly conformal dosimetry while improving dose sparing to Organs at Risk (OARs). Achieving the dose constraints listed in national and international guidelines can be challenging. This report validates the achievability of these constraints and brings a clinical context to these guidelines.Methods
A retrospective analysis of 43 clinician approved plans was conducted. These plans were evaluated against the Radiation Therapy Oncology Workgroup (RTOG) 0529, eviQ, the Assessment of New Radiation Oncology Treatments and Technologies (ANROTAT) and departmental protocol. A constraint was considered 'pass' if it met an ideal objective or minor violation. A constraint was considered 'failed' if a major violation occurred.Results
RTOG 0529 Planning Target Volumes (PTV) constraints D98 ≥ 80% and D95 ≥ 90% of the Total Dose (TD) were achieved in 100% of our patient cohort, with a median of 93.8% and 96% TD for the high-risk PTV (54Gy) and 92.6% and 95.2% TD for the low-risk PTV (45Gy). The stricter ANROTAT D98 ≥ 90% TD was achieved in 93% of our patient cohort for the high-risk PTV (54Gy) and 77% for the low-risk PTV (45Gy). Major violations of the gastrointestinal (GI) OAR constraints were observed in up to 40% of the plans. While there were no strict major violation specifications for skeletal and genitourinary (GU) OARs, dose constraint non-compliance occurred in up to 19% and 56% of the plans respectively.Conclusions
Although VMAT is the gold standard for anal SCC, achieving the recommended dose constraints was challenging. Further refinement of dose constraints is essential to ensure the clinical achievability of planning objectives.
Related
- Fictive Field-based Feathering for Extended-SSD Total Body Irradiation: A Single-institution Planning and Dosimetric Analysis
- Comparative Dosimetric Evaluation of Tomotherapy with a 1-cm Field Width versus Volumetric-modulated Arc Therapy for Whole-brain Radiotherapy with Hippocampal Avoidance
- Deep Learning-based Volumetric Modulated Arc Therapy Dose Prediction with Uncertainty Quantification for Left- and Right-sided Breast Cancer: A Single-institution Feasibility Study
- Dosimetric Comparison of One-, Two-, Three-, and Four-Arc Volumetric Modulated Arc Therapy Plans in Cervical Carcinoma: Evaluation of Plan Quality, Organ-at-Risk Sparing, and Treatment Efficiency.
- Dosimetric and Treatment Delivery Efficiency Comparison of Two Ring-gantry Linear Accelerator Platforms for Liver Stereotactic Body Radiotherapy
BibTeX
@article{alshamrani2026dosimetric,
title = {{Dosimetric Outcomes of Definitive Radiation Therapy to Anal Squamous Cell Carcinoma in a Single Institution Using Volumetric Modulated Arc Therapy Evaluated Against Australian and International Treatment Planning Guidelines}},
author = {Faisal Alshamrani and Michael Hsieh and Anthony Karl and Lauren Chamberlain and Stuart Greenham and Josie Goodworth and Maree Wood and Thomas Shakespeare and Tue Le and Abdul Mohd Tahir},
journal = {Journal of Medical Radiation Sciences},
year = {2026},
month = oct,
doi = {10.1002/jmrs.70124},
url = {https://europepmc.org/article/PMC/PMC13717669},
note = {CC BY},
}
RIS
TY - JOUR
TI - Dosimetric Outcomes of Definitive Radiation Therapy to Anal Squamous Cell Carcinoma in a Single Institution Using Volumetric Modulated Arc Therapy Evaluated Against Australian and International Treatment Planning Guidelines
AU - Faisal Alshamrani
AU - Michael Hsieh
AU - Anthony Karl
AU - Lauren Chamberlain
AU - Stuart Greenham
AU - Josie Goodworth
AU - Maree Wood
AU - Thomas Shakespeare
AU - Tue Le
AU - Abdul Mohd Tahir
PY - 2026
DA - 2026/10/29
JO - Journal of Medical Radiation Sciences
DO - 10.1002/jmrs.70124
UR - https://europepmc.org/article/PMC/PMC13717669
AB - Introduction Volumetric Modulated Arc Therapy (VMAT) is the technique of choice for anal Squamous Cell Carcinoma (SCC), offering highly conformal dosimetry while improving dose sparing to Organs at Risk (OARs). Achieving the dose constraints listed in national and international guidelines can be challenging. This report validates the achievability of these constraints and brings a clinical context to these guidelines.Methods A retrospective analysis of 43 clinician approved plans was conducted. These plans were evaluated against the Radiation Therapy Oncology Workgroup (RTOG) 0529, eviQ, the Assessment of New Radiation Oncology Treatments and Technologies (ANROTAT) and departmental protocol. A constraint was considered 'pass' if it met an ideal objective or minor violation. A constraint was considered 'failed' if a major violation occurred.Results RTOG 0529 Planning Target Volumes (PTV) constraints D98 ≥ 80% and D95 ≥ 90% of the Total Dose (TD) were achieved in 100% of our patient cohort, with a median of 93.8% and 96% TD for the high-risk PTV (54Gy) and 92.6% and 95.2% TD for the low-risk PTV (45Gy). The stricter ANROTAT D98 ≥ 90% TD was achieved in 93% of our patient cohort for the high-risk PTV (54Gy) and 77% for the low-risk PTV (45Gy). Major violations of the gastrointestinal (GI) OAR constraints were observed in up to 40% of the plans. While there were no strict major violation specifications for skeletal and genitourinary (GU) OARs, dose constraint non-compliance occurred in up to 19% and 56% of the plans respectively.Conclusions Although VMAT is the gold standard for anal SCC, achieving the recommended dose constraints was challenging. Further refinement of dose constraints is essential to ensure the clinical achievability of planning objectives.
SN - 2051-3895
SN - 2051-3909
ER -